CoQ10 and Blood Pressure: Does CoQ10 Lower Blood Pressure?

CoQ10 and blood pressure have been studied for decades, but the size of the effect depends heavily on which evidence you read. Older trials reported dramatic reductions in blood pressure. Modern meta-analyses generally suggest a much smaller average effect—mostly on systolic blood pressure—and some rigorous reviews and randomized trials find no significant benefit at all.

Direct answer: CoQ10 may lower systolic blood pressure by roughly 3–5 mmHg on average in some pooled randomized evidence, but the result is heterogeneous and not consistent across every population. Diastolic effects are smaller and less reliable. CoQ10 is not a replacement for antihypertensive medication, and the older claims of 10–20 mmHg reductions should not be treated as a typical expectation.

If you need the foundation first, read What Is CoQ10?, CoQ10 Benefits and CoQ10 Side Effects, Safety & Interactions.

CoQ10 and blood pressure at a glance

Question	Evidence-based answer
Does CoQ10 lower blood pressure?	Possibly. Several modern meta-analyses find a small average reduction in systolic blood pressure, while other strict reviews and trials are null.
How much might systolic BP fall?	Positive modern pooled estimates are generally around 3–5 mmHg on average, not the 10–20 mmHg sometimes quoted from older studies.
What about diastolic BP?	Less consistent. Several meta-analyses find no significant pooled reduction, although one 2025 type 2 diabetes meta-analysis reported about a 2.7 mmHg reduction.
Strongest recent broad meta-analysis	Karimi 2025 pooled 45 RCTs and found about a 3.4 mmHg systolic reduction; diastolic pressure and heart rate were not significantly changed.
Strict primary-hypertension review	The 2016 Cochrane review found no significant systolic or diastolic benefit, but only two small trials with 50 participants could be pooled.
Ambulatory BP evidence	A 2012 randomized crossover trial using 24-hour ambulatory monitoring found no significant primary systolic or diastolic effect.
Studied doses	Trials use varied regimens, commonly around 100–200 mg/day in blood-pressure research. No universal optimal dose is established.
Can it replace BP medication?	No. CoQ10 has not been shown to replace evidence-based antihypertensive therapy or prevent cardiovascular events as a substitute treatment.

Does CoQ10 lower blood pressure?

The best current answer is sometimes, modestly, and not consistently.

That is less exciting than the supplement-marketing version, but it fits the full randomized evidence. Some studies show clinically noticeable reductions. Others show little or no effect. When dozens of randomized trials are pooled, the average result usually moves toward a small systolic reduction rather than a dramatic antihypertensive effect.

This distinction matters because a 3–5 mmHg average change can still be biologically relevant at a population level, but it is not enough to justify telling an individual patient that CoQ10 will control hypertension.

Blood pressure is also not one endpoint. Systolic pressure, diastolic pressure, office readings, home readings and 24-hour ambulatory blood pressure answer related but different questions. The CoQ10 literature does not perform equally well on all of them.

Why would CoQ10 affect blood pressure?

There are several plausible mechanisms.

• Endothelial function: CoQ10 participates in redox biology and may support nitric-oxide-dependent vasodilation.
• Oxidative stress: reduced CoQ10, or ubiquinol, participates in lipid-phase antioxidant systems that can influence vascular redox balance.
• Mitochondrial function: CoQ10 is an electron carrier in oxidative phosphorylation and may affect energy-dependent vascular processes.
• Arterial function: some human studies show improvements in flow-mediated dilation and related vascular surrogate measures.

These mechanisms make a blood-pressure effect plausible. They do not prove that a supplement lowers blood pressure enough to improve clinical outcomes.

The evidence chain still has to move from mechanism → vascular change → measured blood-pressure change → cardiovascular outcome. CoQ10 has evidence at the earlier steps and mixed evidence at the blood-pressure step. It has not been shown to prevent strokes or heart attacks specifically because it lowers blood pressure.

Why older CoQ10 studies reported huge blood-pressure reductions

Some of the numbers still repeated online come from a much older evidence base.

The Rosenfeldt 2007 meta-analysis included 12 clinical studies with 362 patients. Its randomized-trial subset suggested roughly 16.6 mmHg lower systolic and 8.2 mmHg lower diastolic pressure. The crossover and open-label studies also reported large reductions.

Those findings made CoQ10 look almost like a conventional antihypertensive drug. But the review mixed three randomized trials, one crossover study and eight open-label studies. That creates substantial room for regression to the mean, expectation effects, treatment changes and other biases.

An individual older trial, Burke 2001, randomized 83 adults with isolated systolic hypertension to CoQ10 120 mg/day or placebo for 12 weeks and reported an average systolic reduction of about 17.8 mmHg.

That result should not be erased. It is real published randomized evidence. But it is also much larger than the effects seen in modern pooled analyses. When an older small-trial literature and newer larger syntheses disagree on magnitude, the safer estimate is not the most dramatic number.

What do randomized blood-pressure trials show?

Hodgson 2002: a positive trial in type 2 diabetes

The Hodgson 2002 randomized trial studied 74 people with type 2 diabetes using 200 mg/day CoQ10 for 12 weeks. It reported reductions of approximately 6.1 mmHg systolic and 2.9 mmHg diastolic compared with control.

This supports a genuine antihypertensive signal in at least some cardiometabolic populations. But one trial cannot define the average response across all forms of hypertension.

Young 2012: 24-hour ambulatory blood pressure was negative

The Young 2012 randomized double-blind crossover trial is especially important because it used 24-hour ambulatory blood-pressure monitoring, which is less vulnerable to isolated office-reading effects.

Thirty hypertensive adults with metabolic syndrome received 200 mg/day CoQ10 or placebo while continuing stable conventional therapy. The prespecified 24-hour systolic outcome was not significantly reduced (P=0.60), and the diastolic outcome was also null (P=0.12).

Selected secondary blood-pressure-load measures moved favorably, but the primary ambulatory outcomes did not. This trial is a useful counterweight to older office-BP studies showing very large reductions.

What do the CoQ10 blood-pressure meta-analyses show?

Review	Evidence base	Main BP result	Best interpretation
Rosenfeldt 2007	12 clinical studies / 362 patients	Very large systolic and diastolic reductions	Historically important positive signal, but many included studies were open-label and the magnitude is not supported by modern pooled evidence.
Cochrane 2016	2 pooled strict RCTs / 50 participants	SBP −3.68 mmHg and DBP −2.03 mmHg; neither statistically significant	Methodologically strict but severely underpowered; does not establish benefit.
Tabrizi 2018	17 RCTs / 684 participants with metabolic disease	Small significant systolic effect; diastolic effect not significant	Supports a systolic signal across metabolic populations, but effect-size interpretation is limited by heterogeneity.
Zhao 2022 dose-response analysis	26 studies / 1,831 participants	SBP about −4.77 mmHg	Supports a modest average systolic effect; dose-response modeling suggested a stronger signal around 100–200 mg/day.
Li 2025	16 RCTs in type 2 diabetes	SBP −3.86 mmHg; DBP −2.70 mmHg	Positive diabetes-specific result, but heterogeneity was very high.
Karimi 2025	45 RCTs	SBP about −3.4 mmHg; DBP not significantly changed	Largest modern broad synthesis supports a modest systolic—not dramatic—effect.
Rezagholizadeh 2026	20 eligible RCTs in prediabetes/type 2 diabetes	No significant pooled SBP or DBP effect	Recent GRADE-assessed null result showing that even diabetes-specific pooled evidence is unstable.

Why do the 2025 and 2026 diabetes meta-analyses disagree?

This is exactly the sort of evidence conflict that gets hidden when supplement content cites only one favorable review.

The 2025 Li meta-analysis pooled 16 randomized trials in type 2 diabetes and reported significant reductions in both systolic and diastolic blood pressure. The systolic estimate was −3.86 mmHg and the diastolic estimate −2.70 mmHg.

Yet the newer 2026 GRADE-assessed review, covering 20 eligible randomized trials in prediabetes and type 2 diabetes, found no significant pooled systolic or diastolic effect.

The correct conclusion is not that one review must be fraudulent or useless. Systematic reviews can reach different results because they use different search windows, eligibility rules, trial sets, statistical models and outcome definitions. Both papers also sit on top of a heterogeneous small-trial literature.

For consumers, the useful implication is simple: the blood-pressure effect is not stable enough to promise a specific reduction to an individual patient.

Why office blood pressure and 24-hour ambulatory pressure are not the same

Blood pressure changes throughout the day and can rise temporarily in a clinic. That is why a treatment that changes one or two office measurements does not necessarily produce the same change across 24 hours.

Ambulatory monitoring repeatedly measures blood pressure during normal daily life and sleep. It can therefore provide a more robust picture of total blood-pressure exposure.

This distinction makes the null Young 2012 ambulatory trial particularly relevant. It does not disprove every positive office-BP study, but it weakens the idea that CoQ10 reliably produces a large sustained antihypertensive effect.

Does CoQ10 lower systolic blood pressure more than diastolic pressure?

That is the overall pattern in the modern literature.

Systolic blood pressure is the top number and reflects arterial pressure during ventricular contraction. Diastolic blood pressure is the bottom number and reflects pressure during cardiac relaxation.

The broad 2025 Karimi meta-analysis found a significant systolic reduction but not a significant diastolic reduction. The 2018 Tabrizi meta-analysis showed a similar pattern. The 2022 dose-response synthesis also produced a clearer systolic signal.

The 2025 Li diabetes meta-analysis is an exception because both systolic and diastolic values were significantly reduced. The newer 2026 diabetes synthesis was null for both.

So if someone asks, “What is the best-supported CoQ10 blood-pressure effect?” the answer is: a small average reduction in systolic pressure, with less consistent evidence for diastolic pressure.

How much can CoQ10 lower blood pressure?

The best estimate depends on the population and review, but modern positive pooled evidence generally points to roughly 3–5 mmHg lower systolic pressure on average.

That is very different from saying every person will drop five points. Meta-analysis averages combine responders, nonresponders and people whose pressure may move in either direction.

It is also very different from the older claims of 15–18 mmHg reductions. Those large results came from a smaller and methodologically weaker evidence base and should not be presented as the expected effect in 2026.

A modest average reduction can still matter biologically. But if a person's blood pressure is substantially above target, relying on a supplement with a variable single-digit effect is not an evidence-based substitute for established hypertension care.

What is the best CoQ10 dosage for high blood pressure?

No universal optimal dose has been established.

Relevant human studies include:

• 120 mg/day: the positive older Burke isolated-systolic-hypertension trial.
• 200 mg/day: the positive Hodgson type 2 diabetes trial.
• 200 mg/day: the null Young ambulatory-blood-pressure crossover trial.

The 2022 dose-response meta-analysis modeled a stronger systolic signal around 100–200 mg/day. The 2025 Karimi review also found a stronger subgroup effect at doses at or below 200 mg/day.

Those subgroup and dose-response analyses are useful for generating hypotheses. They are not the same as a large randomized trial assigning patients to 100, 200, 300 and 400 mg/day and proving which dose is clinically optimal.

For a wider discussion of research doses, see CoQ10 Dosage.

How long does CoQ10 take to affect blood pressure?

The relevant blood-pressure studies evaluate repeated supplementation over weeks to months, not an acute one-dose effect.

That is another reason CoQ10 should not be treated like an emergency blood-pressure intervention. A person with severely elevated pressure needs appropriate clinical assessment; waiting to see whether a supplement lowers the number over several weeks is not a safe substitute.

For ordinary supplementation, consistency and meal context are more evidence-based considerations than choosing one exact clock time. See Best Time to Take CoQ10.

Can CoQ10 replace blood-pressure medication?

No.

CoQ10 has not been shown to replace established antihypertensive drugs or to produce the same cardiovascular-outcome evidence as appropriate medical treatment.

The distinction between a blood-pressure surrogate and a patient-important outcome matters here. A supplement can reduce systolic pressure by a few millimeters of mercury without having demonstrated fewer strokes, heart attacks, heart-failure events or deaths as a hypertension treatment.

If someone taking antihypertensive medication wants to try CoQ10, the appropriate question is whether it can be used safely as an adjunct while blood pressure is monitored—not whether it can justify stopping prescribed therapy.

Can CoQ10 make blood pressure too low?

A major hypotensive effect is not common or guaranteed, but an additive effect is biologically possible—especially in a person whose blood pressure is already well controlled with medication.

New dizziness, lightheadedness, faintness or unusually low home readings after adding a supplement deserve review. Do not respond by independently stopping a prescribed antihypertensive; the clinician managing the regimen can determine whether the medication, supplement, hydration status or another factor is responsible.

For broader medication and safety context, read CoQ10 Side Effects, Safety & Interactions.

Is ubiquinol better than ubiquinone for blood pressure?

No head-to-head clinical trial has established one redox form as superior for lowering blood pressure.

Ubiquinol and ubiquinone are interconvertible forms of CoQ10. Some ubiquinol formulations produce higher plasma exposure than some ubiquinone products, while optimized ubiquinone formulations can also perform very well.

But this page is about blood pressure, not plasma pharmacokinetics. Higher CoQ10 exposure does not automatically mean a larger blood-pressure reduction.

See Ubiquinol vs Ubiquinone for the direct formulation evidence.

Who should be especially cautious with CoQ10 for blood pressure?

• People already taking multiple antihypertensive medications, particularly if home readings sometimes run low.
• People with dizziness, fainting or orthostatic symptoms.
• People taking warfarin, because the interaction evidence is conflicting and anticoagulation should be managed deliberately.
• People using insulin or glucose-lowering medication, because CoQ10 can affect metabolic outcomes in some populations.
• People with significant cardiovascular or kidney disease, where blood-pressure targets and medication choices need individualized management.
• Pregnant or breastfeeding patients, because routine safety evidence is incomplete.

Common myths about CoQ10 and high blood pressure

Myth: CoQ10 is a natural blood-pressure medicine

That phrase is too strong. CoQ10 is a supplement with mixed randomized evidence and a modest pooled systolic signal. It has not demonstrated the outcome evidence required to replace antihypertensive medication.

Myth: CoQ10 lowers systolic blood pressure by 17 mmHg

Some older trials reported reductions of that magnitude. Modern pooled evidence is much smaller, generally around 3–5 mmHg in positive analyses. The older number should not be advertised as the expected effect.

Myth: 100–200 mg/day is the proven optimal dose

Not proven. Dose-response and subgroup analyses suggest a possible stronger signal in that range, but they do not establish one universal treatment dose.

Myth: Ubiquinol must work better because it is better absorbed

Formulation can change absorption, but no head-to-head clinical evidence establishes superior blood-pressure lowering from ubiquinol.

Myth: If CoQ10 lowers blood pressure, it must prevent strokes

A change in a surrogate endpoint does not automatically establish cardiovascular-event reduction. Disease-outcome claims require direct clinical-outcome evidence.

Myth: A negative Cochrane review means CoQ10 definitely does nothing

Also too strong. The 2016 Cochrane review was methodologically strict, but only two trials with 50 participants could be pooled. It failed to establish benefit; it did not precisely rule out a small effect.

Final verdict: should you take CoQ10 for blood pressure?

CoQ10 may modestly lower systolic blood pressure in some people, but it is not a reliable stand-alone treatment for hypertension.

The broad modern evidence supports a possible average systolic reduction of roughly 3–5 mmHg. That signal appears in large meta-analyses, but it is accompanied by high heterogeneity, less consistent diastolic effects, a negative 24-hour ambulatory trial and a strict Cochrane review that did not establish significant benefit.

The two newest diabetes-focused meta-analyses even disagree with one another: Li 2025 found modest systolic and diastolic reductions, while Rezagholizadeh 2026 found no significant pooled blood-pressure effect. That disagreement is not a nuisance to hide—it is the central reason the recommendation should remain cautious.

So the evidence-based hierarchy is: use proven hypertension treatment when indicated; treat CoQ10, at most, as a possible adjunct; monitor the actual blood-pressure response; and do not assume a mechanism, a dose-response subgroup or one positive study guarantees benefit.

For the underlying positive, negative and conflicting studies, browse the 72-paper CoQ10 Research Data Center.

Continue the CoQ10 evidence trail

• What Is CoQ10?
• CoQ10 Benefits
• CoQ10 Dosage
• Best Time to Take CoQ10
• CoQ10 Side Effects, Safety & Interactions
• CoQ10 and Statins
• Ubiquinol vs Ubiquinone
• CoQ10 Research Data Center

Medical note: This article summarizes clinical research and does not prescribe treatment. If you have diagnosed hypertension, very high blood pressure, symptoms such as chest pain or severe headache, or take prescription blood-pressure medication, use individualized medical guidance rather than replacing treatment with a supplement.